ArticleBrain research2012
Stabilin-1 expression in tumor associated macrophages.
Article in Brain research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Extracellular Matrix Remodeling in Tumors: Forces Beyond Fibroblasts.Cancer research · 2026Article
- Stabilin‑1: An immunoregulatory scavenger receptor in inflammation and tissue homeostasis (Review).Molecular medicine reports · 2026Review
- Article
- Clever-1 positive macrophages in breast cancer.Breast cancer research and treatment · 2022Article
- Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy.Journal of cancer research and clinical oncology · 2021Review
- Review
- Microlocalization and clinical significance of stabilin-1World journal of urology · 2020Article
- Accumulation of stabilin-1 positive macrophages in the early stage of gastric cancer is associated with short cumulative survival.Oncology letters · 2020Article
- Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.Cellular & molecular immunology · 2020Review
- Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.Investigational new drugs · 2017Article
- A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.BMC genomics · 2017Article
- Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model.Oncotarget · 2016Article
- Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.Advances in cancer research · 2015Review
- Molecular biomarkers for grass pollen immunotherapy.World journal of methodology · 2014Review
- Expression of stabilin-1 in M2 macrophages in human granulomatous disease and melanocytic lesions.International journal of clinical and experimental pathology · 2014Article
- Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis.Frontiers in physiology · 2014Review
- Review
- Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.ASN neuroArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma multiforme is a very aggressive and common form of brain tumor. Current therapies consist of a combination of surgical removal, chemotherapy and radiation therapy. These drastic treatments still leave a current prognosis of median survival of less than 1 year. Lack of effectiveness of these treatments has left researchers looking for alternative forms of treatment. A significant alternative currently being investigated is the use of the immune system to potentially target and eliminate tumor cells directly. Stabilin-1, a scavenger receptor expressed by macrophages, has the potential in inhibiting tumor growth by binding and internalizing secreted protein acidic and rich in cysteine (SPARC). SPARC is known to be upregulated in the tumor microenvironment and is involved in extracellular matrix remodeling, cell proliferation and migration. Decreasing SPARC expression using siRNA has been shown to decrease tumor invasiveness and survival. We investigated the phenotype of stabilin-1 expressing immune cells in the tumor environment and demonstrated a transient population of alternatively activated macrophages expressing stabilin-1 in the tumor environment and the disappearance of that population as the tumor progresses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.